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Abstract
Cardiovascular disease is the leading cause of death in developed countries and is one of the leading causes of disease burden
in developing countries. Therapies have markedly increased survival in several categories of patients, nonetheless mortality still
remains high. For this reason high hopes are associated with recent developments in stem cell biology and regenerative medicine
that promise to replace damaged or lost cardiac muscle with healthy tissue, and thus to dramatically improve the quality of life
and survival in patients with various cardiomyopathies.
Much of our insight into the molecular and cellular basis of cardiovascular biology comes from small animal models,
particularly mice. However, significant differences exist with regard to several cardiac characteristics when mice are compared
with humans. For this reason, large animal models like dog, sheep and pig have a well established role in cardiac research. A
distinct characteristic of cardiac stem cells is that they can either be endogenous or derive from outside the heart itself; they can
originate as the natural course of their differentiation programme (e.g., embryonic stem cells) or can be the result of specific
inductive conditions (e.g., mesenchymal stem cells). In this review we will summarize the current knowledge on the kind of
heart-related stem cells currently available in large animal species and their relevance to human studies as pre-clinical models.
© 2011 Elsevier Inc. All rights reserved.
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1. The promises of cell therapy for heart diseases
Cardiovascular disease is the leading cause of death
in developed countries and is one of the leading causes
of disease burden in developing countries [1,2], se-
verely affecting quality of life and decreasing life ex-
pectancy. It is a consequence of ischemic and non-
ischemic cardiomyopathies, usually associated with left
ventricular dysfunction. A rising heart failure incidence
is associated with unhealthy lifestyles and increasing
population age. Current therapies are essentially symp-
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tomatic and, even though they provide some survival
benefit, they cannot reverse the loss of contractile car-
diac tissue due to ischemic injury.
For this reason high hopes are associated with the
recent developments in stem cell biology and regener-
ative medicine that promise to replace damaged or lost
cardiac muscle with healthy tissue, and thus to dramat-
ically improve the quality of life and survival in pa-
tients with various cardiomyopathies.
Until a few years ago, this was considered impossible,
as the heart was thought to be an organ composed of
terminally differentiated myocytes incapable of regenera-
tion. Indeed, this can still be hard to believe based on
everyday experience, which indicates a grossly inadequate
regenerative capacity of human myocardium to compen-
sate for the loss of heart muscle presented by myocardial
infarction or other myocardial diseases.
However, evidence creates the general consensus
that transplantation of progenitor cells of different ori-
gin can theoretically improve ventricular function after
injury [3], although whether or not current in vitro and
animal studies provide enough evidence to warrant
clinical trials is hotly debated.
Much of our insight into the molecular and cellular
basis of cardiovascular biology comes from small ani-
mal models, particularly mice. However, significant
differences exist with regard to several cardiac charac-
teristics when mice are compared with humans [4].
An important parameter is heart rate, with an adult
mouse heart beating 500–600 times per minute, com-
pared with the 60–100 times typical of the human. This
extends to other functional parameters summarized in
Table 1.
Apart from size, human and murine hearts differ
in coronary architecture, the variations of which are
much bigger in humans compared with mice. As a
consequence, whereas the size and location of the
ischemic area are fairly constant in the mouse, a
much larger variation exists in the human [5]. Dif-
ferences can also be appreciated at the cellular level,
as indicated by the higher capillary density observed
in the mouse than in the human heart and by the
larger cross sectional area of the myocytes in the
human than in the mouse [6,7].
Important differences continue at the molecular
level: humans have a high level of -myosin heavy
chain isoform, whereas mice have a high level of the
-myosin heavy chain isoform compared with the
total myofibrillar myosin protein in the ventricles
[8,9]. This, in turn suggests a possible difference in
the mechanical behavior of the myocardium between
the two species [10].
Consequently, extrapolation of murine systems, par-
ticularly after induction of cardiovascular stress, has
some obvious limits that can be crucial the closer it gets
to a clinical application.
Therefore, it is generally acknowledged that large
animal models, which more closely approximate hu-
man physiology, function and anatomy, are essential to
develop the discoveries from murine models into clin-
ical therapies and interventions for heart therapies [4].
Here we review the advantages and limitations of
using large animal models when attempting to bridge
the gap between new basic science discoveries in stem
cell research and their translation into new clinical
treatments.
2. Which animal for which pathology?
We have briefly mentioned that human and mouse
heart present some important differences but it must be
said that the so called large animal models are an
heterogeneous group and, as such, there is no single
perfect animal model (Table 1).
Dogs are becoming an increasingly popular model
due to their behavior and ease of handling. Investiga-
tions on myocardial ischemia and infarction have his-
torically relied on observations performed on adult
dogs, leading to the identification of fundamental pa-
rameters such as the time course to myocite irreversible
injury with increasing period of ischemia moving from
endocardium towards the epicardium [11]. Research on
dogs built the foundation on which current reperfusion
treatment guidelines for acute coronary syndromes
were developed and provided proof of concept for
thrombolytic therapy. Physiological similarities with
humans extend to the endocrine system enabling the
study of the cardioprotective effect of drugs modulating
the renin-angiotensin pathway [12]. However relation
between heart size and body weight in the dog com-
pared to human is almost twice and, on the other hand,
Table 1
Comparison of indicative anatomy and physiology data between






Human 360–480 gr 60–90 60–120 mm Hg
Mouse 0.14–0.15 gr 500–600 80–160 mm Hg
Rabbit 9–11 gr 120–300 70–170 mm Hg
Dog 160–420 gr 60–120 120–150 mm Hg
Pig 400–500 gr 65–75 70–130 mm Hg
Sheep 240–360 gr 70–80 80–120 mm Hg
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dog heart has a collateral coronary circulation approx-
imately four times more extended than that of man,
making it difficult to obtain a consistent degree of
myocardial injury following experimental ischemia and
to reliably extrapolate to human the post-infarction
course observed in dogs [13].
Pig seems to differ from man in its predisposition for
refractory arrhythmogenesis, providing an altered re-
sponse to myocardial infarction, although methods are
available to reduce the impact of this issue [14].
When it comes to heart vascularisation, detailed ana-
tomical studies show that the pig is by far the best model.
In fact not only the coronary anatomy but even the poor
subendocardial to epicardial collateral network of the
swine heart are very similar to that of humans [15]. Minor
differences have only been described in the septal arteries:
the anterior ones provide most of the irroration in man,
whereas in the porcine heart, anterior and posterior arter-
ies share the septal ventricular vascularisation almost
equally [16]. Most of the pig studies have been performed
using ameroid constrictors leading to a progressive coro-
nary stenosis with late occlusion with consequent myo-
cardial ischemia and ventricular dysfunction, but heart
failure could be produced only by using acute coronary
occlusion. Such extensive similarities allowed us to per-
form studies that evaluated the re-establishment of stable
collateral networks and improved myocardial perfusion in
response to the administration of angiogenic growth fac-
tors [17].
When postinfarction congestive heart failure is to be
studied, the sheep is a better model because lack of col-
lateral blood flow to the infarcted area, maintenance of
normal blood flow to uninfarcted areas, and the moderate
size of the infarcted myocardium allow us to faithfully
reproduce the three major clinical causes of this pathology
[18]. This has greatly contributed to the understanding of
differing outcomes dependent on specific locations of MI
creation [19]. Limitations of working with sheep, being
ruminants, derive from their gastrointestinal anatomy and
thoracic contours that are substantially different from
those of monogastric species. This can make certain im-
aging approaches difficult, specifically ultrasonic imaging
that requires an invasive approach as opposed to transtho-
racic imaging applicable to other models.
3. The many stem cells available for heart
regeneration
A distinct characteristic of cardiogenic stem cells is
that they can be either endogenous or derive from
outside the heart itself, can originate as the natural
course of their differentiation programme (e.g., embry-
onic stem cells) or can be the result of specific inductive
conditions (e.g., mesenchymal stem cells). Why so
many cell types have a cardiogenic potential, at least in
vitro, is not clear. This can reflect the requirement for a
specific precursor of each of the cell types that are
found in the heart including cardiomyocytes, endothe-
lial cells, smooth muscle cells, conduction system cells
as well as neurons, or it can simply mimic the process
of cardiac differentiation, where a variety of progenitor
cells contribute to new cardiac tissue at different stages
of embryonic development.
The following are the better characterized cardiac
exogenous progenitor cells. Mesenchymal stem cells
(MSC) are mainly found in the bone marrow stroma
and in adipose tissue, are multipotent, can be easily
amplified in culture and differentiate efficiently into
different cell types including adipocytes, chondrocytes,
osteoblasts and endothelial cells [20]. Despite the fact
that they differentiate into contracting cardiomyocytes
with low efficiency, MSC administration leads to a
significant functional improvement and to a lower mor-
tality rate in a canine model of AMI [21]. However, the
ability of MSCs to transdifferentiate into cardiomyo-
cytes is highly controversial [22] and their beneficial
effect is thought to derive mainly from their influence
on neovascularization of the ischemic tissue and their
protection of resident cells [23]. This property, together
with their low immunogenicity [24], make MSCs an
efficient cellular vehicle for delivering therapeutic sub-
stances to the myocardial lesion [25], promoting their
use in allogeneic recipients as well.
Skeletal myoblasts, or satellite cells, are the endog-
enous stem cell population that efficiently maintains
homeostasis in skeletal muscle [26]; they are easy to
isolate and propagate in vitro. The similarity between
skeletal and cardiac muscle cells suggests that satellite
cells should be able to switch towards a cardiomyocyte
fate once inside the ventricular tissue. However, even
if the administration of satellite cells brings the for-
mation of contracting cells, these largely fail to form
intercalated disks and appropriate gap junctions with
resident cardiomyocytes [27], often causing serious
arrhythmias [28].
Bone marrow-derived progenitor cells (BMPCs) are
a heterogeneous mixture that comprises endothelial
progenitor cells, mononuclear bone marrow cells and
CD34-positive cells. BMPCs have been administered to
patients affected by acute myocardial infarction or
chronic ischemic heart failure with positive effects on
cardiac function and documented safety of this thera-
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peutic approach [29]. These cells constitute an appeal-
ing source of cardiac precursors because they can be
easily collected from bone marrow aspirates or from the
peripheral blood. However, BMPCs plasticity and their
ability to acquire the cardiomyocyte lineage after in-
farction is still controversial [30].
Embryonic stem cells (ESC) and, more recently,
induced Pluripotent Stem cells (iPS) have been shown
to be able to differentiate in vitro into genuine cardio-
myocytes and supportive cardiac cells [31,32] as well
as to integrate into heart tissue, improving cardiac func-
tion [33,34]. However, ESC and iPS also have disad-
vantages that may limit their use in clinical settings.
Possibly the most serious is their propensity to develop
teratomas, tumors that contain a variety of different
tissues [35]. Furthermore ES/iPS cells differentiate into
heterogeneous populations, where cardiac cells repre-
sent approximately 1%. It is therefore necessary to
improve this efficiency and to obtain heart specialized
cell types, such as ventricular and atrial myocytes, or
pacemaker and conduction system cells [36]. Finally,
grafted ESC form a syncytium but usually become
separated from the myocardium by a layer of fibrotic
tissue. This prevents a proper electrical coupling, and is
a major risk factor for arrhythmias [37]. Most of these
limitations, however, could be overcome by the re-
cently reported derivation of induced cardiomyocytes
(iCM) [38]. These new cells were obtained by trans-
fecting postnatal cardiac fibroblasts (the most common
cell type in the heart) with a combination of three
developmental transcription factors (i.e., Gata4, Mef2c
and Tbx5). Induced cardiomyocytes express cardiac-
specific markers, have a global gene expression profile
similar to cardiomyocytes and contract spontaneously.
Since the reprogramming protocol does not involve, in
this instance, a pluripotent embryonic-like status, these
cells should not have the propensity to develop terato-
mas. Furthermore, should it be possible to reprogram
the heart fibroblasts in situ, the functional integration of
the newly generated cardiomyocytes will be greatly
enhanced.
The heart has always been considered a terminally
differentiated postmitotic organ, but recent studies
demonstrated that cardiac homeostasis is maintained by
a local cell population known as resident cardiac stem
cells (CSCs) [39] confirming in mammals what was
already known in teleost fish and amphibians, where
heart regeneration is a much more evident phenomena
[40]. As mentioned above, CSCs are also a heteroge-
neous group composed of different members mostly
lacking unequivocal markers for their identification.
Side population (SP) cells are a typical example,
being identified by their inability to take up staining by
the vital dyes Hoechst 3342 and rhodamine 123. SP
cells are multipotent and have been identified not only
in the heart but also in the bone marrow, skeletal
muscle and adipose tissue [41]. Following a myocardial
infarction, the number of SP cells in the mouse heart
increases through proliferation of resident SP cells, as
well as homing of BM-derived SP cells [42].
Cells positive to c-Kit surface antigen are located in
small clusters within the ventricles and atria of the adult
heart and, when transplanted in an injured cardiac tis-
sue, differentiate into cardiomyocytes, endothelial cells
and smooth muscle cells [43,44]. CSCs also include
cells expressing stem cell antigen 1 (SCA-1) but not
c-Kit, a rare cell population SCA-1/cKit as well as
another Sca-1/CD31 cell type. Cells derived from
the secondary heart field during embryonic develop-
ment persist, in small numbers, in the adult organ and
are marked by the expression of Isl1. Isl1 cells can
give rise to cardiomyocytes, smooth muscle and endo-
thelial cells [45].
CSCs are derived from small heart biopsies
through a delicate enzymatic digestion that releases
round cells which in turn form round bodies in sus-
pension culture, called cardiospheres. Upon trans-
plantation into damaged heart tissue, these cells dif-
ferentiate into vascular and cardiac cells and exert
positive paracrine effects [46].
Finally, both endothelial [47] and epicardial [48]
cells become activated after injury and give rise to
cardiac, vascular and myofibroblast/smooth muscle
cells resuming their capacity during development.
4. Which cardiac stem cells are available in large
animal models, and do they actually work?
After having described the morphological and func-
tional similarities that make large animal models a well
established and useful tool in cardiac research, and
having described the different kind of cardiogenic stem
cells, we now summarize which cells are available in
the different species (Fig. 1).
Rabbit was one of the first species used to investi-
gate the possibility of myocardial tissue regeneration.
Early work tested the use of autologous transplantation
of skeletal myoblasts (satellite cells) and observed the
capacity of these cells to partially restore the function
of damaged tissue [49,50]. More recently, rabbit has
been used to investigate bone marrow-derived stem
cells (BMCs). Results indicated that autologous BMCs
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improve global contractility and enhance myocardial
remote capillary density and collagen content even if
BMCs failed to transdifferentiate into new cardiomyo-
cytes [51]. A more specialized cell population, bone
marrow mononuclear cells (BMMNCs), has also been
derived in rabbit, and used for intracoronary injection
resulting in a substantial delay of collagen metabolism
and a decrease of the myocardial collagen volume frac-
tion [52]. Rabbit MSCs are also available and provide
an effective improvement of cardiac function [53].
Dog cardiac stem cells are available from different
sources. Furthermore, in this species skeletal muscle
satellite cells were one of the first cell types to be
isolated and tested for their capacity to regenerate dam-
aged myocardial tissue providing proof of principle
studies on the safety and efficacy of this method
[54,55].
One of the most investigated cell type is the bone
marrow-derived MSC that has the important advantage
of eliciting a very mild immune response and can there-
fore be used in heterologous transplants with no need of
immunosuppressive treatments [21]. Dog MSCs can
also undergo cardiomyogenic specification by ex vivo
pre-treatment with specific growth factors, thus im-
proving their regenerative properties [56]. These cells
have positive effects when administered after both an
acute or chronic myocardial ischaemia [21,57].
Very recent data demonstrate that it is possible to
derive dog endothelial progenitor cells and, thanks to
the anatomical similarities described above, it was pos-
sible to demonstrate that these cells can also be admin-
istered effectively following subendocardial injections,
a clinically more practical route of administration [58].
The dog heart also possesses an endogenous cardiac
stem cell (CSC) pool characterized by undifferentiated
cells that are self-renewing, clonogenic and multipotent
[59]. As described for the corresponding human cells
[43] canine CSCs express c-kit, MDR1, and Sca-1-like
antigens suggesting that results obtained in the dog are
likely to be relevant to man. Dog CSCs can also form
three-dimensional cell aggregates, so called cardio-
spheres, whose regenerative properties are currently
under investigation [60].
Sheep mesenchymal stem cells can be easily derived
as in other large animal models [61]. In this species the
perivascular STRO-3 positive mesenchymal precursor
cells (MPCs), a small fraction of mesenchymal stem
cells that demonstrate an extensive capacity for prolif-
eration and differentiation, have also been identified
and tested for their regenerative properties [62].
Sheep is often used to study the possibility to use
MSC for cardiac valve regeneration in association with
bioabsorbable valved patches [63,64]. Bone marrow
mononuclear cells (BMMC) have been used to create in
Fig. 1. Human cardiac stem cells can be either endogenous or derive from outside the heart itself like satellite cells, different kind of mesenchymal
stem cells, or embryonic/iP stem cells. However, whereas satellite cells and many different kind of mesenchymal cell types are available in every
large animal model species, cardiac progenitor cells have been derived only in dog and pig. At present no ESC/iPS cells are available in any of
these species.
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vitro tissue-engineered heart valves based on a decel-
lularized porcine scaffold then tested in autologous
transplantats [65]. Endothelial progenitor cells (EPCs)
have also been used as a cell source for the creation of
tissue-engineered heart valves in sheep [66].
Skeletal myoblast can be derived and propagated
in vitro in sheep as described in other species and
large areas of grafted cells can be found within the
myocardial lesion, however the cells maintain the
histological features of well-differentiated skeletal
muscle cells [67].
Pig cardiogenic stem cells are the most studied. In
this species all sort of bone marrow-derived stem cells
are currently available. These include BM-derived
mononuclear cells (BM-MNCs) [68–70], peripheral
blood mononuclear cells (PB-MNCs) [71,72] and BM-
derived mesenchymal stem cells [73]. Bone marrow-
derived MSC have been magnetically labeled in order
to develop non-invasive methods for studying the en-
graftment based on magnetic resonance imaging (MRI)
[74,75]. Pig MSC were used also to explore new de-
livery methods like a patch of a fibrin matrix seeded
with autologous cells [76]. As it was observed in other
species, pig MSCs can be prepared from an allogeneic
donor without being rejected, confirming that these
cells have a major practical advantage for their wide-
spread application in a clinical setting [77] and are also
being tested for proving the safety of an “off-the-shelf”
cellular cardiomyoplasty strategy [78]. In addition, di-
rect intramyocardial injection of MSCs results in suc-
cessful engraftment and differentiation into cardiomy-
ocytes and endothelial cells and preserves left
ventricular function in acute [79] and chronic myocar-
dial lesions [80].
Cardiogenic stem cells have been derived from pig
adipose tissue (ADSCs) and can engraft in the infarcted
region 4 weeks after transcatheter intracoronary cell
transplantation improving cardiac function and perfu-
sion via angiogenesis with an efficiency comparable to
that of bone marrow-derived stem cells [81].
Pig amniotic fluid-derived mesenchymal cells
(AFC) are also available. However, when autotrans-
planted in a porcine model of acute myocardial in-
farction, AFC are able to transdifferentiate to cells of
vascular cell lineages but not to cardiomyocytes [82].
Resident cardiac stem cells (CSC) can be derived
from pig endomyocardial specimens. When pig CSCs
are grown in primary culture they form cardiospheres
that can be plated to obtain cardiosphere-derived cells
(CDCs). CDCs are cardiogenic in vitro as indicated by
spontaneous intracellular calcium transients and action
potentials as well as fast, inward sodium currents, how-
ever, cardiospheres and CDCs do not spontaneously
contract [46].
We have recently isolated a different type of CSC,
the cardiac mesoangioblasts (MABs), from atrium and
aorta explants of the adult pig. Originally identified in
mouse [83] and human hearts [84,85], MABs are com-
mitted to the cardiac lineage and differ from other
stem/progenitor cells types because of marker expres-
sion, isolation method, and differentiation potency.
They have been characterized for the expression of
stemness markers and for the expression of early and
late cardiac markers, endothelial markers and muscular
markers. Pig MABS differentiate into mesodermal cell
types, and can give rise to functional cardiomyocytes
(ISSCR 2009).
5. Delivery methods
The aim of cell therapy is to reach the region of
interest through the best way. Traditionally in heart cell
therapy three ways have been adopted: arterial coronary
administration, percutaneous endocardial or direct
transmyocardial injection [86,87]. Experimental data
demonstrate that MSCs and progenitors cells can reach
the diseased area through the intracoronary infusion
even though high dose could obstruct the microcircu-
lation with consequent embolic myocardial episodes.
Endo- and epicardial routes seem to remain the best
way to reach the target even if the epicardial cell ad-
ministration remain more invasive and could be per-
formed during open heart surgery [88].
6. Conclusions
The development of an effective regenerative ther-
apy of the heart is not likely to be achieved in the near
future since clinical and animal studies show that true
cardiac regeneration does involve more complex as-
pects than injecting the right type of cells in the right
place [3].
Large animal models have a well established role in
cardiovascular research and the derivation of different
types of cardiogenic stem cells in different species
indicated that these models can certainly provide a
substantial contribution to the development of cell ther-
apies. Mesenchymal stem cells of different origin have
proved to be readily available in these species and
showed the same properties of their human counterpart.
More limited, at present, are the data available on
cardiac resident stem cells, but promising results are
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being achieved. On the contrary, the derivation of bona
fide embryonic stem cells is still elusive in these spe-
cies, making large animal models not available for this
very promising cell type. However the recent derivation
of iPS in pig [89,90] may soon be able to overcome this
limitation.
References
[1] Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ.
Global and regional burden of disease and risk factors, 2001:
systematic analysis of population health data. Lancet 2006;367:
1747–57.
[2] Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy
A. Growing epidemic of coronary heart disease in low- and
middle-income countries. Curr Probl Cardiol 2010;35:72–115.
[3] Segers VF, Lee RT. Stem-cell therapy for cardiac disease.
Nature 2008;451:937–42.
[4] Dixon JA, Spinale FG. Large animal models of heart failure: a
critical link in the translation of basic science to clinical prac-
tice. Circ Heart Fail 2009;2:262–71.
[5] Blankesteijn WM, Creemers E, Lutgens E, Cleutjens JP, Dae-
men MJ, Smits JF. Dynamics of cardiac wound healing follow-
ing myocardial infarction: observations in genetically altered
mice. Acta Physiol Scand 2001;173:75–82.
[6] Rakusan K, Nagai J. Morphometry of arterioles and capillaries
in hearts of senescent mice. Cardiovasc Res 1994;28:969–72.
[7] Stoker ME, Gerdes AM, May JF. Regional differences in cap-
illary density and myocyte size in the normal human heart. Anat
Rec 1982;202:187–91.
[8] Doevendans PA, Daemen MJ, de Muinck ED, Smits JF.
Cardiovascular phenotyping in mice. Cardiovasc Res 1998;
39:34 – 49.
[9] Swynghedauw B. Developmental and functional adaptation of
contractile proteins in cardiac and skeletal muscles. Physiol Rev
1986;66:710–71.
[10] Liu W, Ashford MW, Chen J, Watkins MP, Williams TA,
Wickline SA, Yu X. MR tagging demonstrates quantitative
differences in regional ventricular wall motion in mice, rats, and
men. Am J Physiol Heart Circ Physiol 2006;291:H2515–21.
[11] Reimer KA, Jennings RB. The “wavefront phenomenon” of
myocardial ischemic cell death. II. Transmural progression of
necrosis within the framework of ischemic bed size (myocar-
dium at risk) and collateral flow. Lab Invest 1979;40:633–44.
[12] Jugdutt BI, Menon V. Valsartan-induced cardioprotection in-
volves angiotensin II type 2 receptor upregulation in dog and rat
models of in vivo reperfused myocardial infarction. J Card Fail
2004;10:74–82.
[13] White FC, Roth DM, Bloor CM. The pig as a model for
myocardial ischemia and exercise. Lab Anim Sci 1986;36:
351–6.
[14] Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM,
Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough
WM, Zile MR, Spinale FG. Myocardial infarct expansion and
matrix metalloproteinase inhibition. Circulation 2003;107:
618 –25.
[15] Weaver ME, Pantely GA, Bristow JD, Ladley HD. A quantita-
tive study of the anatomy and distribution of coronary arteries in
swine in comparison with other animals and man. Cardiovasc
Res 1986;20:907–17.
[16] Bertho E, Gagnon G. A Comparative Study in Three Dimension
of the Blood Supply of the Normal Interventricular Septum in
Human, Canine, Bovine, Procine, Ovine and Equine Heart. Dis
Chest 1964;46:251–62.
[17] Lu H, Xu X, Zhang M, Cao R, Brakenhielm E, Li C, Lin H, Yao
G, Sun H, Qi L, Tang M, Dai H, Zhang Y, Su R, Bi Y, Cao Y.
Combinatorial protein therapy of angiogenic and arteriogenic
factors remarkably improves collaterogenesis and cardiac func-
tion in pigs. Proc Natl Acad Sci USA 2007;104:12140–5.
[18] Myocardial infarct expansion and matrix metalloproteinase in-
hibition. Circulation 2003;107:618–25.
[19] Gorman JH, 3rd, Gorman RC, Plappert T, Jackson BM, Hira-
matsu Y, St John-Sutton MG, Edmunds LH, Jr. Infarct size and
location determine development of mitral regurgitation in the
sheep model. J Thorac Cardiovasc Surg 1998;115:615–22.
[20] Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R,
Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak
DR. Multilineage potential of adult human mesenchymal stem
cells. Science 1999;284:143–7.
[21] Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D,
Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira
EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal
stem cells differentiate into an endothelial phenotype, enhance
vascular density, and improve heart function in a canine chronic
ischemia model. Circulation 2005;111:150–6.
[22] Rose RA, Keating A, Backx PH. Do mesenchymal stromal cells
transdifferentiate into functional cardiomyocytes? Circ Res
2008;103:e120.
[23] Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in
adult stem cell signaling and therapy. Circ Res 2008;103:
1204 –19.
[24] Aggarwal S, Pittenger MF. Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood 2005;105:
1815–22.
[25] Boudoulas KD, Hatzopoulos AK. Cardiac repair and regenera-
tion: the Rubik’s cube of cell therapy for heart disease. Dis
Model Mech 2009;2:344–58.
[26] Buckingham M, Montarras D. Skeletal muscle stem cells. Curr
Opin Genet Dev 2008;18:330–6.
[27] Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do
not transdifferentiate into cardiomyocytes after cardiac grafting.
J Mol Cell Cardiol 2002;34:241–9.
[28] Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Char-
pak S. Myoblasts transplanted into rat infarcted myocardium are
functionally isolated from their host. Proc Natl Acad Sci USA
2003;100:7808–11.
[29] Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur
A, Watt SM. Autologous bone marrow stem cells to treat acute
myocardial infarction: a systematic review. Eur Heart J 2008;
29:1807–18.
[30] Hosoda T, Kajstura J, Leri A, Anversa P. Mechanisms of myo-
cardial regeneration. Circ J 2010;74:13–7.
[31] Passier R, van Laake LW, Mummery CL. Stem-cell-based ther-
apy and lessons from the heart. Nature 2008;453:322–9.
[32] Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka
S, Yamanaka S, Yamashita JK. Directed and systematic differ-
entiation of cardiovascular cells from mouse induced pluripo-
tent stem cells. Circulation 2008;118:498–506.
[33] Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate
JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S,
O’Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S,
Yuan C, Gold J, Murry CE. Cardiomyocytes derived from
1422 F. Gandolfi et al. / Theriogenology 75 (2011) 1416–1425
Author's personal copy
human embryonic stem cells in pro-survival factors enhance
function of infarcted rat hearts. Nat Biotech 2007;25:1015.
[34] Yan P, Nagasawa A, Uosaki H, Sugimoto A, Yamamizu K,
Teranishi M, Matsuda H, Matsuoka S, Ikeda T, Komeda M,
Sakata R, Yamashita JK. Cyclosporin-A potently induces
highly cardiogenic progenitors from embryonic stem cells.
Biochem Biophys Res Commun 2009;379:115–20.
[35] Nussbaum J. Transplantation of undifferentiated murine embry-
onic stem cells in the heart: teratoma formation and immune
response. FASEB J 2007;21:1345.
[36] Behfar A, Faustino RS, Arrell DK, Dzeja PP, Perez-Terzic C,
Terzic A. Guided stem cell cardiopoiesis: discovery and trans-
lation. J Mol Cell Cardiol 2008;45:523–9.
[37] Laflamme MA, Zbinden S, Epstein SE, Murry CE. Cell-based
cardiac repair: pathophysiologic mechanisms. Annu Rev Pathol
Mech Dis 2007;2:307.
[38] Ieda M, Fu J-D, Delgado-Olguin P, Vedantham V, Hayashi Y,
Bruneau BG, Srivastava D. Direct Reprogramming of Fibro-
blasts into Functional Cardiomyocytes by Defined Factors. Cell
2010;142:375–86.
[39] Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Growth-
factor-mediated cardiac stem cell activation in myocardial re-
generation. Nat Clin Pract Cardiovasc Med 2007;4 Suppl
1:S46–51.
[40] Ausoni S, Sartore S. From fish to amphibians to mammals: in
search of novel strategies to optimize cardiac regeneration. The
Journal of Cell Biology 2009;184:357–64.
[41] Bouchet-Marquis C, Dubochet J, Fakan S. Cryoelectron micros-
copy of vitrified sections: a new challenge for the analysis of
functional nuclear architecture. Histochem Cell Biol 2006;125:
43–51.
[42] Mouquet F, Pfister O, Jain M, Oikonomopoulos A, Ngoy S,
Summer R, Fine A, Liao R. Restoration of cardiac progenitor
cells after myocardial infarction by self-proliferation and selec-
tive homing of bone marrow-derived stem cells. Circ Res 2005;
97:1090–2.
[43] Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F,
Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A,
Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells
are multipotent and support myocardial regeneration. Cell 2003;
114:763–76.
[44] Rota M, Padin-Iruegas ME, Misao Y, De Angelis A, Maestroni
S, Ferreira-Martins J, Fiumana E, Rastaldo R, Arcarese ML,
Mitchell TS, Boni A, Bolli R, Urbanek K, Hosoda T, Anversa
P, Leri A, Kajstura J. Local activation or implantation of cardiac
progenitor cells rescues scarred infarcted myocardium improv-
ing cardiac function. Circ Res 2008;103:107–16.
[45] Laugwitz KL, Moretti A, Caron L, Nakano A, Chien KR. Islet1
cardiovascular progenitors: a single source for heart lineages?
Development 2008;135:193–205.
[46] Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E,
Giacomello A, Abraham MR, Marban E. Regenerative potential
of cardiosphere-derived cells expanded from percutaneous en-
domyocardial biopsy specimens. Circulation 2007;115:896–
908.
[47] Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen
JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB,
Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesen-
chymal transition contributes to cardiac fibrosis. Nat Med 2007;13:
952–61.
[48] van Tuyn J, Atsma DE, Winter EM, van der Velde-van Dijke I,
Pijnappels DA, Bax NA, Knaan-Shanzer S, Gittenberger-de
Groot AC, Poelmann RE, van der Laarse A, van der Wall EE,
Schalij MJ, de Vries AA. Epicardial cells of human adults can
undergo an epithelial-to-mesenchymal transition and obtain
characteristics of smooth muscle cells in vitro. Stem Cells
2007;25:271–8.
[49] Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC,
Hutcheson KA, Glower DD, Kraus WE. Regenerating func-
tional myocardium: improved performance after skeletal myo-
blast transplantation. Nat Med 1998;4:929–33.
[50] Taylor DA, Silvestry SC, Bishop SP, Annex BH, Lilly RE,
Glower DD, Kraus WE. Delivery of primary autologous skeletal
myoblasts into rabbit heart by coronary infusion: a potential
approach to myocardial repair. Proc Assoc Am Physicians
1997;109:245–53.
[51] Garbade J, Dhein S, Lipinski C, Aupperle H, Arsalan M, Borger
MA, Barten MJ, Lehmann S, Walther T, Mohr F-W. Bone
Marrow-Derived Stem Cells Attenuate Impaired Contractility
and Enhance Capillary Density in a Rabbit Model of Doxoru-
bicin-Induced Failing Hearts. J Card Surg 2009;24:591–9.
[52] Jin B, Luo XP, Ni HC, Li Y, Shi HM. Cardiac matrix remod-
eling following intracoronary cell transplantation in dilated car-
diomyopathic rabbits. Mol Biol Rep 2010;37:3037–42.
[53] Xu Y-L, Gao Y-H, Liu Z, Tan K-B, Hua X, Fang Z-Q, Wang
Y-L, Wang Y-J, Xia H-M, Zhuo Z-X. Myocardium-targeted
transplantation of mesenchymal stem cells by diagnostic ultra-
sound-mediated microbubble destruction improves cardiac
function in myocardial infarction of New Zealand rabbits. Int
J Cardiol 2010;138:182–95.
[54] Yoon PD, Kao RL, Magovern GJ. Myocardial regeneration.
Transplanting satellite cells into damaged myocardium. Tex
Heart Inst J 1995;22:119–25.
[55] Chiu RC, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myo-
cardial regeneration with satellite cell implantation. Ann Thorac
Surg 1995;60:12–8.
[56] Bartunek J, Croissant JD, Wijns W, Gofflot S, de Lavareille A,
Vanderheyden M, Kaluzhny Y, Mazouz N, Willemsen P,
Penicka M, Mathieu M, Homsy C, De Bruyne B, McEntee K,
Lee IW, Heyndrickx GR. Pretreatment of adult bone marrow
mesenchymal stem cells with cardiomyogenic growth factors
and repair of the chronically infarcted myocardium. Am J
Physiol Heart Circ Physiol 2007;292:H1095–104.
[57] Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson
MD. Intra-coronary arterial injection of mesenchymal stromal
cells and microinfarction in dogs. Lancet 2004;363:783–4.
[58] Mitchell AJ, Sabondjian E, Sykes J, Deans L, Zhu W, Lu X,
Feng Q, Prato FS, Wisenberg G. Comparison of initial cell
retention and clearance kinetics after subendocardial or subepi-
cardial injections of endothelial progenitor cells in a canine
myocardial infarction model. J Nucl Med 2010;51:413–7.
[59] Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nas-
cimbene A, Castaldo C, Cascapera S, Bohm M, Quaini F,
Urbanek K, Leri A, Hintze TH, Kajstura J, Anversa P. Stem
cells in the dog heart are self-renewing, clonogenic, and multi-
potent and regenerate infarcted myocardium, improving cardiac
function. Proc Natl Acad Sci USA 2005;102:8966–71.
[60] Bartosh TJ, Wang Z, Rosales AA, Dimitrijevich SD, Roque RS.
3D-model of adult cardiac stem cells promotes cardiac differ-
entiation and resistance to oxidative stress. J Cell Biochem
2008;105:612–23.
[61] Weir, Morel-Kopp MC, Gill A, Tinworth K, Ladd L, Hunyor
SN, Ward C. Mesenchymal stem cells: isolation, characterisa-
1423F. Gandolfi et al. / Theriogenology 75 (2011) 1416–1425
Author's personal copy
tion and in vivo fluorescent dye tracking. Heart Lung Circ
2008;17:395–403.
[62] Hamamoto H, Gorman JH, 3rd, Ryan LP, Hinmon R, Martens
TP, Schuster MD, Plappert T, Kiupel M, St John-Sutton MG,
Itescu S, Gorman RC. Allogeneic mesenchymal precursor cell
therapy to limit remodeling after myocardial infarction: the
effect of cell dosage. Ann Thorac Surg 2009;87:794–801.
[63] Kalfa D, Bel A, Chen-Tournoux A, Della Martina A, Rochereau
P, Coz C, Bellamy V, Bensalah M, Vanneaux V, Lecourt S,
Mousseaux E, Bruneval P, Larghero J, Menasche P. A poly-
dioxanone electrospun valved patch to replace the right ventric-
ular outflow tract in a growing lamb model. Biomaterials 2010;
31:4056–63.
[64] Sutherland FW, Perry TE, Yu Y, Sherwood MC, Rabkin E,
Masuda Y, Garcia GA, McLellan DL, Engelmayr GC, Jr., Sacks
MS, Schoen FJ, Mayer JE, Jr.From stem cells to viable autol-
ogous semilunar heart valve. Circulation 2005;111:2783–91.
[65] Vincentelli A, Wautot F, Juthier F, Fouquet O, Corseaux D,
Marechaux S, Le Tourneau T, Fabre O, Susen S, Van Belle E,
Mouquet F, Decoene C, Prat A, Jude B. In vivo autologous
recellularization of a tissue-engineered heart valve: are bone
marrow mesenchymal stem cells the best candidates? J Thorac
Cardiovasc Surg 2007;134:424–32.
[66] Sales VL, Mettler BA, Engelmayr GC, Jr., Aikawa E, Bischoff
J, Martin DP, Exarhopoulos A, Moses MA, Schoen FJ, Sacks
MS, Mayer JE, Jr. Endothelial progenitor cells as a sole source
for ex vivo seeding of tissue-engineered heart valves. Tissue
Eng Part A 2010;16:257–67.
[67] Ghostine S, Carrion C, Souza LC, Richard P, Bruneval P,
Vilquin JT, Pouzet B, Schwartz K, Menasche P, Hagege AA.
Long-term efficacy of myoblast transplantation on regional
structure and function after myocardial infarction. Circulation
2002;106:I131–36.
[68] Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y,
Ozono R, Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A,
Shintani S, Murohara T, Imaizumi T, Iwasaka T. Implantation
of bone marrow mononuclear cells into ischemic myocardium
enhances collateral perfusion and regional function via side
supply of angioblasts, angiogenic ligands, and cytokines. Cir-
culation 2001;104:1046–52.
[69] Bhakta S, Greco NJ, Finney MR, Scheid PE, Hoffman RD,
Joseph ME, Banks JJ, Laughlin MJ, Pompili VJ. The safety of
autologous intracoronary stem cell injections in a porcine model
of chronic myocardial ischemia. J Invasive Cardiol 2006;18:
212–8.
[70] Makela J, Ylitalo K, Lehtonen S, Dahlbacka S, Niemela E,
Kiviluoma K, Rimpilainen J, Alaoja H, Paavonen T, Lehenkari
P, Juvonen T, Anttila V. Bone marrow-derived mononuclear
cell transplantation improves myocardial recovery by enhancing
cellular recruitment and differentiation at the infarction site.
J Thorac Cardiovasc Surg 2007;134:565–73.
[71] Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K,
Iba O, Imada T, Iwasaka T. Improvement of collateral perfusion
and regional function by implantation of peripheral blood
mononuclear cells into ischemic hibernating myocardium. Ar-
terioscler Thromb Vasc Biol 2002;22:1804–10.
[72] Doyle B, Sorajja P, Hynes B, Kumar AH, Araoz PA, Stal-
boerger PG, Miller D, Reed C, Schmeckpeper J, Wang S, Liu C,
Terzic A, Kruger D, Riederer S, Caplice NM. Progenitor cell
therapy in a porcine acute myocardial infarction model induces
cardiac hypertrophy, mediated by paracrine secretion of car-
diotrophic factors including TGFbeta1. Stem Cells Dev
2008;17:941–51.
[73] Pak HN, Qayyum M, Kim DT, Hamabe A, Miyauchi Y, Lill
MC, Frantzen M, Takizawa K, Chen LS, Fishbein MC, Sharifi
BG, Chen PS, Makkar R. Mesenchymal stem cell injection
induces cardiac nerve sprouting and increased tenascin expres-
sion in a Swine model of myocardial infarction. J Cardiovasc
Electrophysiol 2003;14:841–8.
[74] Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin
BJ, Pittenger MF, Hare JM, Bulte JW. In vivo magnetic reso-
nance imaging of mesenchymal stem cells in myocardial infarc-
tion. Circulation 2003;107:2290–3.
[75] He G, Zhang H, Wei H, Wang Y, Zhang X, Tang Y, Wei Y, Hu
S. In vivo imaging of bone marrow mesenchymal stem cells
transplanted into myocardium using magnetic resonance imag-
ing: a novel method to trace the transplanted cells. Int J Cardiol
2007;114:4–10.
[76] Liu J, Hu Q, Wang Z, Xu C, Wang X, Gong G, Mansoor A, Lee
J, Hou M, Zeng L, Zhang JR, Jerosch-Herold M, Guo T, Bache
RJ, Zhang J. Autologous stem cell transplantation for myocar-
dial repair. Am J Physiol Heart Circ Physiol 2004;287:H501–
11.
[77] Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS,
Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke
S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM.
Cardiac repair with intramyocardial injection of allogeneic mes-
enchymal stem cells after myocardial infarction. Proc Natl Acad
Sci USA 2005;102:11474–9.
[78] Poh KK, Sperry E, Young RG, Freyman T, Barringhaus KG,
Thompson CA. Repeated direct endomyocardial transplantation
of allogeneic mesenchymal stem cells: safety of a high dose,
“off-the-shelf”, cellular cardiomyoplasty strategy. Int J Cardiol
2007;117:360–4.
[79] Makkar RR, Price MJ, Lill M, Frantzen M, Takizawa K, Kleisli
T, Zheng J, Kar S, McClelan R, Miyamota T, Bick-Forrester J,
Fishbein MC, Shah PK, Forrester JS, Sharifi B, Chen PS,
Qayyum M. Intramyocardial injection of allogenic bone mar-
row-derived mesenchymal stem cells without immunosuppres-
sion preserves cardiac function in a porcine model of myocar-
dial infarction. J Cardiovasc Pharmacol Ther 2005;10:225–33.
[80] Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet
JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick
B, Conte JV, McNiece I, Steenbergen C, Lardo AC, Hare JM.
Autologous mesenchymal stem cells produce reverse remodel-
ling in chronic ischaemic cardiomyopathy. Eur Heart J 2009;
30:2722–32.
[81] Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ,
Le Jemtel TH, Alt E. Intracoronary administration of autologous
adipose tissue-derived stem cells improves left ventricular func-
tion, perfusion, and remodelling after acute myocardial infarc-
tion. Eur Heart J 2007;28:2667–77.
[82] Sartore S, Lenzi M, Angelini A, Chiavegato A, Gasparotto L,
De Coppi P, Bianco R, Gerosa G. Amniotic mesenchymal cells
autotransplanted in a porcine model of cardiac ischemia do not
differentiate to cardiogenic phenotypes. Eur J Cardiothorac
Surg 2005;28:677–84.
[83] Galvez BG, Sampaolesi M, Barbuti A, Crespi A, Covarello D,
Brunelli S, Dellavalle A, Crippa S, Balconi G, Cuccovillo I,
Molla F, Staszewsky L, Latini R, Difrancesco D, Cossu G.
Cardiac mesoangioblasts are committed, self-renewable progen-
itors, associated with small vessels of juvenile mouse ventricle.
Cell Death Differ 2008;15:1417–28.
1424 F. Gandolfi et al. / Theriogenology 75 (2011) 1416–1425
Author's personal copy
[84] Barbuti A, Galvez BG, Crespi A, Scavone A, Baruscotti M, Brios-
chi C, Cossu G, DiFrancesco D. Mesoangioblasts from ventricular
vessels can differentiate in vitro into cardiac myocytes with sino-
atrial-like properties. J Mol Cell Cardiol 2010;48:415–23.
[85] Galvez BG, Covarello D, Tolorenzi R, Brunelli S, Dellavalle A,
Crippa S, Mohammed SA, Scialla L, Cuccovillo I, Molla F,
Staszewsky L, Maisano F, Sampaolesi M, Latini R, Cossu G.
Human cardiac mesoangioblasts isolated from hypertrophic car-
diomyopathies are greatly reduced in proliferation and differ-
entiation potency. Cardiovasc Res 2009;83:707–16.
[86] Pendyala L, Goodchild T, Gadesam RR, Chen J, Robinson K,
Chronos N, Hou D. Cellular Cardiomyoplasty and Cardiac Re-
generation. Curr Cardiol Rev 2008;4:72–80.
[87] Aicher A, Brenner W, Zuhayra M, et al. Assessment of the
tissue distribution of transplanted human endothelial progenitor
cells by radioactive labeling. Circulation 2003;107:2134–9.
[88] Vulliet PR, Greeley M, Halloran SM, et al. Intracoronary arte-
rial injection of mesenchymal stromal cells and microinfarction
in dogs. Lancet 2004;363:783–4.
[89] Wu Z, Chen J, Ren J, Bao L, Liao J, Cui C, Rao L, Li H, Gu Y,
Dai H, Zhu H, Teng X, Cheng L, Xiao L. Generation of pig
induced pluripotent stem cells with a drug-inducible system. J
Mol Cell Biol 2009;1:46–54.
[90] Roberts RM, Telugu BP, Ezashi T. Induced pluripotent stem
cells from swine (Sus scrofa): why they may prove to be
important. Cell Cycle 2009;8:3078–81.
1425F. Gandolfi et al. / Theriogenology 75 (2011) 1416–1425
